Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ).
Ab&B Bio-Tech CO., LTD. JS announced that its quadrivalent subunit influenza vaccine, Huierkangxin, has been included in the preliminary list of the National Commercial Health Insurance Innovative Drug List for 2025. This vaccine, approved in May 2023, is the first of its kind in China and offers broad protection against four influenza virus strains. The inclusion in the list highlights the vaccine’s significance and potential impact on the market, although the company cautions that there is no guarantee of successful development and marketing for all intended age groups.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a biotechnology company based in China, specializing in the development of innovative vaccines. Its primary product is the quadrivalent subunit influenza vaccine, designed to provide comprehensive protection against multiple strains of influenza viruses.
Average Trading Volume: 8,992,780
Find detailed analytics on 2627 stock on TipRanks’ Stock Analysis page.